Left atrial longitudinal strain analysis in diagnostic of cardiotoxicity

Cover Page


Cite item

Abstract

A wide range of extremely effective chemotherapy drugs has a negative effect on the cardiovascular system, leveling oncological treatment success. Early diagnosis of cardiotoxicity is very important, allowing timely application of preventive and therapeutic measures. Left ventricular ejection fraction evaluation using echocardiography is the basic non-invasive instrumental method to assess cardiac function and the main guideline in cardiac dysfunction diagnosis during chemotherapy. However, if dysfunction is subclinical, the ejection fraction can remain normal for a long time, and also has a pronounced inter-operator variability and dependence on volumetric load. Specialists are constantly in search of optimal echocardiographic parameters that allow early-stage cardiac dysfunction diagnosis. Analysis of the global longitudinal deformation of the left atrium seems to be a promising method for these purposes. A large amount of accumulated data suggests that the left atrium is not just a conduit chamber, but a reflection of the filling pressure of the left ventricle, being a sensitive marker of its systolic and diastolic dysfunction. This review presents an analysis of currently available studies on applying the methodology for assessing global longitudinal deformation of the left atrium in cardiac dysfunction diagnosis in the use of cardiotoxic drugs.

Full Text

INTRODUCTION

Advances in modern oncology care have significantly increased the survival of cancer patients over recent decades. New chemotherapy drugs continue to be actively developed and introduced into clinical practice. The methods for detecting and diagnosing early cancer are improving. However, the short-term and long-term side effects of chemotherapy, such as death from heart and vascular diseases, have a significant effect on cancer mortality [1]. According to epidemiological studies, in patients successfully treated for cancer, the risk of cancer recurrence is eventually outweighed by the risk of cardiovascular diseases and their complications [2]. Cardiovascular mortality in childhood cancer survivors increases significantly after the age of 60 yr, which indicates a delayed effect of both the disease itself and treatment consequences [3]. Therefore, this patient population is the increasing focus of general practitioners and cardiologists. This is related to the general population aging as well as the fact that most cancer patients are in the age group of 65 yr and older [4]. As a result, both patients and healthcare systems have an increased burden, including financial [5].

It is now clear that this population requires a multidisciplinary approach. Cardio-oncology is a relatively new therapeutic area that focuses on patients receiving various types of cancer treatments that carry potential risks to the cardiovascular system. The systematic approach of this rapidly developing healthcare field is focused on screening, risk stratification, prevention, follow-up, and treatment of patients receiving chemotherapy and radiological treatment [6]. Cardiotoxicity is not limited to damage to the left ventricle (LV). It can be manifested by rhythm disturbances, damage to the pericardium and heart valves, coronary arteries, as well as arterial and pulmonary hypertension [7]. Simultaneously, some chemotherapy drugs cause rapid and early damage to the cardiovascular system, while side effects of other drugs appear only in many years [8]. Studies demonstrate the significance of the early detection of heart dysfunction (HD) signs, which in turn helps initiate timely treatment and prevent irreversible cardiac damage [9]. Echocardiography (Echo) plays a leading role in the diagnosis of this condition.

ECHOCARDIOGRAPHY FOR THE DIAGNOSIS OF CARDIOTOXICITY

Echocardiography is the basic diagnostic method in cardio-oncology. Measuring left ventricular ejection fraction (LVEF) using two-dimensional echocardiography remains one of the main tools in diagnosing cardiotoxicity signs and symptoms due to its availability and safety. It does, however, have some limitations, such as the inter-operator variability and the effect of image quality on the result. The ejection fraction (EF) is a volume-dependent parameter, and this often becomes critical for cancer patients, who are often hypovolemic due to vomiting, diarrhea, and loss of appetite [10]. LVEF does not change until the complete exhaustion of compensation mechanisms and significant myocardial damage, which makes it difficult to diagnose early cardiotoxicity using only this parameter [11].

The two-dimensional speckle-tracking Echo with global longitudinal strain (GLS) evaluations of the LV improves the diagnosis of HD, including the subclinical form, by diagnosing even minimal changes in LV function [12]. However, this parameter is also dependent on preload [13]. The LV strain is well reproducible in serial measurements and can be useful in identifying risk groups for heart damage, watchful waiting, and early decision-making on the initiation of cardioprotective therapy [12, 14].

Currently, there is the concept of a strain-oriented strategy in oncological cardioprotection [15]. A randomized, controlled, multicenter study (Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes) [10] was conducted from 2014 to 2019 and included 331 patients treated with anthracyclines. The results of this study were inconsistent. In the group of strain-oriented and conventional cardioprotective strategies, the EF was not statistically significantly different at the end of the study, so the primary endpoint was not reached. The subgroup sub-analysis revealed that LV strain-guided cardioprotective treatment significantly reduced a meaningful fall of LVEF to the abnormal range [16]. These results highlight the need for further research to determine whether the LV strain may be better than EF in identifying selected patient populations who would benefit from cardioprotective treatment to prevent cancer therapy-associated HD [10].

In 2021, the British Society of Echocardiography and the British Cardio-Oncology Society defined the following Echo criteria for cardiotoxicity: a decline in LVEF by >10% (absolute percentage points) from baseline to a value <50% (LVEF of 50 up to 54% is considered borderline and requires further information to decide if there is HD). When it comes to LV strain, a decline of <15% is considered abnormal, while only one episode of such decrease should be interpreted considering the whole clinical picture, as well as additional data, such as laboratory markers and results of other imaging techniques [17]. The authors of these guidelines emphasize that there are “grey zones” that can be seen in both the subclinical HF and normal condition, despite the integral Echo assessment of contractile function.

DIASTOLIC FUNCTION AND CARDIOTOXICITY

The measurement of diastolic function is also recommended in patients receiving cardiotoxic treatment, but its prognostic role is still unclear. Diastolic dysfunction, which is characterized by increased LV filling pressure, significantly increased the risk of cardiovascular events in the general population [18]. Studies in cancer patients demonstrate inconsistent results and are often limited by a small sample size and a high heterogeneity of chemotherapy regimens.

The meta-analysis by M. Nagiub et al. [19] studied the predictive ability of diastolic parameters in the detection of doxorubicin-induced cardiomyopathy and showed that Doppler parameters E (p = 0.003), E/A ratio (p < 0.0001), lateral e’ (p < 0.005), and s’ (p = 0.01) were significantly associated with the systolic function worsening in this group of patients over a long follow-up period. However, the authors highlighted that only 4 of the 17 studies included in the meta-analysis were optimally designed and had all serial diastolic measurements.

A prospective study by J.N. Upshaw et al. (n = 362) [20] also studied changes in diastolic parameters during treatment with anthracyclines with/without trastuzumab. Study participants demonstrated a persistent diastolic function deterioration with decrease in the E/A ratio, lateral and septal e’ velocity, and increase in the E/e’ ratio E/e’ (p < 0.01) by Month 6. The abnormal diastolic function was observed in 60% of cases after 1 yr, 70% after 2 yr, and 80% after 3 yr. The impaired function was associated with a subsequent decrease in LVEF and progressive longitudinal deformity of the LV. The authors concluded that comprehensive breast cancer therapy is associated with a moderate persistent deterioration in diastolic function with a low risk of the subsequent HD.

A meta-analysis of 13 studies (n = 892) by R.I. Mincu et al. [21] demonstrated that in patients without pre-existing heart disease who received anthracyclines, treatment had a modest effect on the E/A ratio (p < 0.001) with no change in e’ and E/e’. The authors of this meta-analysis point to multiple limitations of studies and their heterogeneity with the high risk of bias, so randomized trials are required with large samples using new echocardiographic parameters (such as diastolic strain).

The aforementioned studies of diastolic function in patients receiving cardiotoxic treatment indicate the need for more careful monitoring of cancer patients and identifying an abnormal diastolic profile. Further research is also needed.

To sum up, we can say that there are still some questions, gaps, and “grey zones” related to the echocardiographic diagnosis of HD associated with the use of cardiotoxic drugs with a focus on its early signs, which should be detected to prevent irreversible myocardial damage.

LEFT ATRIUM FUNCTION AND CARDIOTOXICITY

Cardiac imaging professionals are constantly looking for available reproducible techniques and parameters that can be routinely used in clinical practice for the consistent serial evaluation with minimal inter-operator variability and maximum angle- and volume-independence. It is important to note the growing interest of researchers in the function of the left atrium (LA). Large studies have demonstrated an independent predictive value of LA size in patients with heart failure, so this parameter can be considered a possible global prognostic indicator of the population [22, 23]. After developing the invasive techniques, such as 3D and speckle tracking Echo, it became clear that the LA is not just a conduit chamber for filling the LV. The close dynamic relationship between the LV and the LA makes it a kind of mirror reflecting the function of the LV and modulates its filling pressure through the reservoir, conduit, and contractile phases [24, 25]. The LA adapts to changes in the LV compliance by changing its own function and mechanics [26]. Over the past decade, there has been a rapid increase in publications on using speckle-tracking Echo for LA strain assessment. These data are used to assess both diastolic and atrial functions [27, 28]. The method demonstrates a good correlation with computed tomography and magnetic resonance imaging of the heart as well as with invasive measurements [29–31]. Although the deformation of the LA is not completely independent of the preload, its conditions appear to have less effect on the deformation of the LA than on its volume [32]. Simultaneously, different phases of LA contraction have some specific characteristics. For example, reservoir and contractile functions decrease until the symptoms of heart failure occur, the LA dilates, and non-invasive LV filling pressure increases, which allows to diagnose the diastolic dysfunction at the preclinical stage [33]. Evidence has been obtained during the past 10 yr in favor of using changes in parameters of the GLS of the LA as the only marker of LV diastolic dysfunction [28, 34]. We can say that LA deformity, indicating LV compliance, can be used as a significant indicator of LA dysfunction and an early marker of diastolic dysfunction when general echocardiographic parameters are still normal [35]. A meta-analysis by F. Pathan et al. [36], which included 30 studies (with 2,038 healthy volunteers), demonstrated the following normal levels of global longitudinal LA strain parameters: reservoir strain (ƐR) 39% (95% confidence interval (CI) 38–41), contractile strain (ƐCT) 18% (95% CI 16–19), and conduit strain (ƐCD) 23% (95% CI 21–25).

In cardio-oncological imaging, the LA function remained unstudied for a long time, since the focus was completely shifted to the LV. Its function (volume) was indirectly evaluated by examination of diastolic function. In recent years, the LA strain analysis has attracted the close attention of specialists involved in the diagnosis of cardiotoxicity.

The very first study of LA strain and cardiotoxicity was conducted in 2013 by I. Monteet al. [37] in a small sample of patients with multiple sclerosis (n = 20) treated with mitoxantrone. This prospective study showed a decrease in the global LA strain by the end of treatment (10 months vs. 0 months: 15.2 ± 12.5 vs. 20.2 ± 11.1, p < 0.05). Cardiotoxic anthracycline drugs and epidermal growth factor inhibitors were the main focus of the subsequent studies, but other groups have also been studied. For example, the study by A. Sonaglioni et al. [38] included patients (n = 28) receiving bevacizumab (an inhibitor of the biological activity of vascular endothelial growth factor) for bowel cancer. Echo was performed before the start of treatment, then after 3 and 6 months with measuring positive and negative LA strain (ƐCD and ƐCT). After 6 months, no statistically significant changes in the parameters were observed. In subgroups of patients developing cardiotoxicity-associated HD, it was found that in patients with HD, basal echocardiographic characteristics indicating increased LV filling pressure were statistically significantly higher, including a higher E/e’ ratio (p = 0.01) and lower baseline ƐCD (p = 0.007). Accordingly, the observed changes could be predictors of HD. Similar data were obtained in a prospective study by J. Meloche et al. (n = 51) [39]: In nine patients who achieved the cardiotoxicity criteria, treatment with anthracyclines and trastuzumab was associated with a lower basal ƐR (50.0% ± 9.6% vs. 45.6% ± 4.9%, p = 0.058) and ƐCT (30.1% ± 8.0% vs. 24.3% ± 4.6%, p = 0.008). Of them, seven demonstrated an increase in ƐCT, probably due to compensating the reduced LV function. At all phases of treatment, this group of patients showed an early decrease in LA function: ƐCT by Month 3 (29.5 ± 7.6 vs. 27 ± 8.5, p = 0.008), ƐR (49.7% ± 8.8% vs. 44.4% ± 10.4%, p < 0.001), and ƐCT (20.2% ± 4.6% vs. 17.3% ± 5.3%, p < 0.001) by Month 6.

R. Emerson et al. (n = 51) [40], M. Laufer-Perl et al. (n = 40) [41], S. Moustafa et al. (n = 68) [42], J. and Moreno et al. (n = 52) [43] showed a statistically significant decrease in LA strain during anthracycline therapy with or without the addition of trastuzumab. E. Setti et al. (n = 64) [44] found that ƐR and LA volumes can predict the EF trend during 6 months of trastuzumab treatment.

In contrast, S. Moustafa et al. (n = 56) [45] and Y. Anqi et al. (n = 40) [46] found no differences in parameters of LA function associated with chemotherapy. In the first study [45], this can be explained by using a tyrosine kinase inhibitor as a study drug, which does not have a direct toxic effect on the heart muscle and has rather toxic effects on vessels. In the second study [46], authors pointed out that anthracyclines were administered in low doses, although the decrease in LVEF (p < 0.05) and LV strain (p < 0.05) reached statistical significance. A.T. Timóteo et al. [47] (n = 77) also did not find any difference in the LA deformity. The most significant declining trend was observed in ƐCT, and this is consistent with the data of J. Meloche et al. [39] and M. Laufer-Perl et al. [41]. A retrospective study by H. Park et al. (n = 72) [48] included patients already treated with anthracyclines. They were subsequently divided into those who developed (n = 13) and did not develop (n = 59) HD. Basal echocardiographic findings were the same. At the end of chemotherapy, LV strain (p = 0.002) and ƐR (p < 0.001) decreased statistically significantly in both groups. In ROC analysis, 11.7% was the optimal ƐR reduction for predicting future HD, with sensitivity and specificity superior to LV strain. D. di Lisi et al. [49] (n = 102) assessed LA strain, and they were the first who determined index of LA stiffness (a new potential predictive index, which is the E/e′ to ƐR ratio). None of the patients developed clinical signs of HD. However, 53% of the patients had subclinical dysfunction, so they were divided into two groups (with and without dysfunction). In both groups, an early increase in the index of LA stiffness (p < 0.0001) and a decrease in ƐR (p < 0.0001) were observed. The authors concluded that these parameters could detect the early subclinical HD more accurately than the LV strain [49], and their conclusions are consistent with the findings of H. Park et al. [48].

Two cross-sectional studies should be mentioned, which evaluated long-term effects of anthracycline therapy on LA function in childhood cancer survivors. VW Li et al. (n = 26) [50] included men who received anthracycline treatment in childhood (time without chemotherapy 14.2 ± 5.4 yr), and they were compared with age-matched healthy people. Cancer patients had statistically significantly lower maximum (p = 0.009) and minimum (p = 0.017) values of LA volume and ƐCT (p = 0.011). The authors suggested that LA remodeling, which is characterized by a decrease in its contractile function, was caused by LA fibrosis which was induced by anthracycline treatment in childhood.

R.W. Loar et al. [51] compared two groups of sex- and age-matched patients: cancer patients without chemotherapy for more than 1 yr (n = 45) and healthy individuals (n = 45). In the first group, there were statistically significantly lower ƐR values (p = 0.04) compared with controls. The sub-analysis identified 11 patients as the lowest quartile with the lowest ƐR values. In this group, all patients were statistically significantly older than the patients in top three quartiles (p = 0.001), who had no changes in diastolic function and LA strain, regardless of the duration of chemotherapy and doses of anthracyclines. Therefore, age was the only independent predictor of decreased LA function after cancer therapy (p < 0.001). A retrospective observational study by NR Patel et al. [52] showed the opposite results: Of 55 children, only those under 12 yr old had statistically significant differences in LA strain before/after chemotherapy (p = 0.01). As a result, the long-term effects of ongoing treatment on LA function have yet to be established, and this will require long-term observational studies.

In conclusion, we would like to present some data from a retrospective study by M. Tadic et al. (n = 92) [53], which showed a decrease in reservoir and conduit functions of the LA (p < 0.001) in cancer patients before the initiation of chemotherapy compared with a control group with comparable characteristics. The authors suggested that cancer itself may be associated with a decrease in LA function, regardless of other characteristics, and consider several hypotheses and potential mechanisms for this relationship, such as inflammation, activation of biohormonal systems, circulation of vasoactive peptides and cytokines, prevalence of smoking in this group, and disease-related changes in lifestyle (in particular, decreased activity).

To sum up, it can be noted that many studies predominantly involve women, whose initial population-based values of LA strain are higher than those of men [54]. The LA strain measurement itself has the following advantages: This is an angle-independent technique; visualization of the LA in the four-chamber position is less susceptible to lung lobe interference; and image artifacts and reverberation occur less frequently [55]. However, this method also has some limitations: The LA is a thin-walled chamber, which makes it difficult to trace the endocardium. Additionally, researchers often “cut off” the projection of the LA, shortening its longitudinal size. Remember that the dependence of the parameter on the frame rate and preload (but less than that of the LV and EF strain). Moreover, special software is required. However, simplicity and prognostic and diagnostic value of this method make it a useful tool for cardio-oncologists.

It is necessary to establish in which cases the serial measurement of the LA strain will provide the greatest advantage and complement echocardiographic findings: when used for the diagnosis of early subclinical cardiotoxicity or delayed effects of chemotherapy or for deciding on the initiation of therapy and monitoring its effectiveness. Answering these questions will require prospective controlled studies in large patient populations.

The active development of new chemotherapeutic drugs provides cardio-oncologists with new challenges. For example, an irreversible tyrosine kinase inhibitor ibrutinib is associated with a high incidence of atrial fibrillation. A recent study by A. Singh et al. [56] showed a good predictive value of LA strain in this population of patients.

Study limitations

In conclusion, limitations of the review should be noted. Most studies reported have small patient populations and are retrospective. In terms of chemotherapy regimens, they are quite heterogeneous. Some patients receive radiation therapy for the thoracic area, which may contribute to changes in echocardiographic parameters.

CONCLUSION

Therefore, currently available studies suggest the potential value of assessing LA deformity in patients receiving chemotherapy with a cardiotoxic effect.

The potential of Echo needs further research. The assessment of LA strain appears to be a promising and useful method in cardio-oncology.

ADDITIONAL INFORMATION

Funding sourse. This article was not supported by any external sources of funding.

Competing interests. The authors declare that they have no competing interests.

Authors’ contribution. A.V. Yusupova ― review idea, literature review, collection and analysis of literary sources; E.S. Yusupov ― literature review, collection and analysis of literary sources. All authors made a substantial contribution to the conception of the work, acquisition, analysis, interpretation of data for the work, drafting and revising the work, final approval of the version to be published and agree to be accountable for all aspects of the work.

×

About the authors

Anastasiya V. Yusupova

Clinical Hospital of St. Luke

Author for correspondence.
Email: yusupova@lucaclinic.ru
ORCID iD: 0000-0002-0763-0537
SPIN-code: 1492-1947
Russian Federation, Saint-Petersburg

Einar S. Yusupov

North-Western District Scientific and Clinical Center named after L.G. Sokolov

Email: usupov_as@mail.ru
ORCID iD: 0000-0002-4716-0314
SPIN-code: 6632-4484

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

References

  1. Herrmann J, Lerman A, Sandhu NP, et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287. doi: 10.1016/J.MAYOCP.2014.05.013
  2. Okwuosa TM, Anzevino S, Rao R. Cardiovascular disease in cancer survivors. Postgrad Med J. 2017;93(1096):82–90. doi: 10.1136/POSTGRADMEDJ-2016-134417
  3. Fidler MM, Reulen RC, Henson K, et al. Population-based long-term cardiac-specific mortality among 34 489 five-year survivors of childhood cancer in Great Britain. Circulation. 2017;135(10):951–963. doi: 10.1161/CIRCULATIONAHA.116.024811
  4. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and s urvivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385. doi: 10.3322/CAAC.21565
  5. Valero-Elizondo J, Chouairi F, Khera R, et al. Atherosclerotic cardiovascular disease, cancer, and financial toxicity among adults in the United States. JACC CardioOncology. 2021;3(2):236–246. doi: 10.1016/J.JACCAO.2021.02.006
  6. Tajiri K, Aonuma K, Sekine I. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. JJCO Japanese J Clin Oncol. 2017;47(8):678–682. doi: 10.1093/jjco/hyx068
  7. Chang HM, Moudgil R, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol. 2017;70(20):2536–2551. doi: 10.1016/j.jacc.2017.09.1096
  8. Armstrong GT, Ross JD. Late cardiotoxicity in aging adult survivors of childhood cancer. Prog Pediatr Cardiol. 2014;36(1-2):19. doi: 10.1016/J.PPEDCARD.2014.09.003
  9. Lati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671–1680. doi: 10.1093/eurheartj/ehw022
  10. Lopez-Mattei JC, Hassan S. The SUCCOUR trial: a cardiovascular imager’s perspective ― American College of Cardiology [Electronic resource]. Available from: https://www.acc.org/latest-in-cardiology/articles/2021/04/16/13/09/the-succour-trial. Accessed: 15.02.2022.
  11. Laufer-Perl M, Gilon D, Kapusta L, Iakobishvili Z. The role of speckle strain echocardiography in the diagnosis of early subclinical cardiac injury in cancer patients ― is there more than just left ventricle global longitudinal strain? J Clin Med. 2021;10(1):154. doi: 10.3390/JCM10010154
  12. Laufer-Pearl M, Arnold JH, Mor L, et al. The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy. Clin Res Cardiol. 2020;109(2):255–262. doi: 10.1007/S00392-019-01508-9
  13. Choi JO, Shin DH, Cho SW, et al. Effect of preload on left ventricular longitudinal strain by 2D speckle tracking. Echocardiography. 2008;25(8):873–879. doi: 10.1111/j.1540-8175.2008.00707.x
  14. Santoro C, Arpino G, Esposito R, et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging. 2017;18(8):930–936. doi: 10.1093/ehjci/jex033
  15. Santoro C, Esposito R, Lembo M, et al. Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. Eur Heart J Cardiovasc Imaging. 2019;20(12):1345–1352. doi: 10.1093/ehjci/jez194
  16. Thavendiranathan P, Negishi T, Somerset E, et al. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol. 2021;77(4):392–401. doi: 10.1016/j.jacc.2020.11.020
  17. Dobson R, Ghosh AK, Ky B, et al. BSE and BCOS guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. JACC CardioOncology. 2021;3(1):1–16. doi: 10.1016/J.JACCAO.2021.01.011
  18. Kuznetsova T, Thijs L, Knez J, et al. Prognostic value of left ventricular diastolic dysfunction in a general population. J Am Hear Assoc Cardiovasc Cerebrovasc Dis. 2014;3(3):e000789. doi: 10.1161/JAHA.114.000789
  19. Nagiub M, Nixon JV, Kontos MC. Ability of nonstrain diastolic parameters to predict doxorubicin-induced cardiomyopathy: a systematic review with meta-analysis. Cardiol Rev. 2018;26(1):29–34. doi: 10.1097/CRD.0000000000000161
  20. Upshaw JN, Finkelman B, Hubbard RA, et al. Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. JACC Cardiovasc Imaging. 2020;13(1):198–210. doi: 10.1016/J.JCMG.2019.07.018
  21. Mincu RI, Lampe LF, Mahabadi AA, et al. Left ventricular diastolic function following anthracycline-based chemotherapy in patients with breast cancer without previous cardiac disease ― a meta-analysis. J Clin Med. 2021;10(17):3890. doi: 10.3390/JCM10173890
  22. Rossi A, Temporelli PL, Quintana M, et al. Independent relationship of left atrial size and mortality in patients with heart failure: an individual patient meta-analysis of longitudinal data (MeRGE Heart Failure). Eur J Heart Fail. 2009;11(10):929–936. doi: 10.1093/EURJHF/HFP112
  23. Benjamin E, D’Agostino R, Belanger A. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation. 1995;92(4):835–841. doi: 10.1161/01.CIR.92.4.835
  24. Thomas L, Marwick HT, Popescu AB, et al. Left atrial structure and function, and left ventricular diastolic dysfunction: JACC state of the art review. J Am Coll Cardiol. 2019;73(15):1961–1977. doi: 10.1016/J.JACC.2019.01.059
  25. Serezhina EK, Obrezan AG. Significance of the echocardiographic evaluation of left atrial myocardial strain for early diagnosis of heart failure with preserved ejection fraction. Kardiologiia. 2021;61(8):68–75. (In Russ). doi: 10.18087/cardio.2021.8.n1418
  26. Kebed KY, Addetia K, Lang RM. Importance of the left atrium: more than a bystander? Heart Fail Clin. 2019;15(2):191–204. doi: 10.1016/j.hfc.2018.12.001
  27. Litwin SE. Left atrial strain: a single parameter for assessing the dark side of the cardiac cycle? JACC Cardiovasc Imaging. 2020;13(10):2114–2116. doi: 10.1016/j.jcmg.2020.07.037
  28. Alekhin МN, Kalinin АО. Diastolic function of the left ventricle: the meaning of left atrium longitudinal strain. Ultrasound Funct Diagnostics. 2020;(3):91–104. (In Russ). doi: 10.24835/1607-0771-2020-3-91-104
  29. Szilveszter B, Nagy AI, Vattay B, et al. Left ventricular and atrial strain imaging with cardiac computed tomography: validation against echocardiography. J Cardiovasc Comput Tomogr. 2020;14(4):363–369. doi: 10.1016/j.jcct.2019.12.004
  30. Kim J, Yum B, Palumbo MC, et al. Left atrial strain impairment precedes geometric remodeling as a marker of post-myocardial infarction diastolic dysfunction. JACC Cardiovasc Imaging. 2020;13(10):2099–2113. doi: 10.1016/j.jcmg.2020.05.041
  31. Pathan F, Zainal Abidin HA, Vo QH, et al. Left atrial strain: a multi-modality, multi-vendor comparison study. Eur Heart J Cardiovasc Imaging. 2021;22(1):102–110. doi: 10.1093/ehjci/jez303
  32. Genovese D, Singh A, Volpato V, et al. Load dependency of left atrial strain in normal subjects. J Am Soc Echocardiogr. 2018;31(11):1221–1228. doi: 10.1016/j.echo.2018.07.016
  33. Brecht A, Oertelt-Prigione S, Seeland U, et al. Left Atrial function in preclinical diastolic dysfunction: two-dimensional speckle-tracking echocardiography ― derived results from the BEFRI trial. J Am Soc Echocardiogr. 2016;29(8):750–758. doi: 10.1016/j.echo.2016.03.013
  34. Lundberg A, Johnson J, Hage C, et al. Left atrial strain improves estimation of filling pressures in heart failure: a simultaneous echocardiographic and invasive haemodynamic study. Clin Res Cardiol. 2019;108:703–715. doi: 10.1007/s00392-018-1399-8
  35. Mandoli GE, Sisti N, Mondillo S, et al. Left atrial strain in left ventricular diastolic dysfunction: have we finally found the missing piece of the puzzle? Heart Fail Rev. 2020;25(3):409–417. doi: 10.1007/s10741-019-09889-9
  36. Pathan F, D’Elia N, Nolan MT, et al. Normal ranges of left atrial strain by speckle-tracking echocardiography: a systematic review and meta-analysis. J Am Soc Echocardiogr. 2017;30(1):59–70.e8. doi: 10.1016/j.echo.2016.09.007
  37. Monte I, Bottari V, Buccheri S, et al. Chemotherapy-induced cardiotoxicity: subclinical cardiac dysfunction evidence using speckle tracking echocardiography. J Cardiovasc Echogr. 2013;23(1):33–38. doi: 10.4103/2211-4122.117983
  38. Sonaglioni A, Albini A, Fossile E, et al. Speckle-tracking echocardiography for cardioncological evaluation in bevacizumab-treated colorectal cancer patients. Cardiovasc Toxicol. 2020;20(6):581–592. doi: 10.1007/s12012-020-09583-5
  39. Meloche J, Nolan M, Amir E, et al. Temporal changes in left atrial function in women with HER2+ breast cancer receivig sequential anthracyclines and trastuzumab therapy. J Am Coll Cardiol. 2018;71(11):A1524. doi: 10.1016/s0735-1097(18)32065-5
  40. Emerson P, Stefani L, Terluk A, et al. Left atrial strain analysis in breast cancer patients post anthracycline (AC). Hear Lung Circ. 2021;30:S196. doi: 10.1016/j.hlc.2021.06.225
  41. Laufer-Perl M, Arias O, Dorfman SS, et al. Left atrial strain changes in patients with breast cancer during anthracycline therapy. Int J Cardiol. 2021;330:238–244. doi: 10.1016/J.IJCARD.2021.02.013
  42. Moustafa S, Murphy K, Nelluri BK, et al. Temporal trends of cardiac chambers function with trastuzumab in human epidermal growth factor receptor ii-positive breast cancer patients. Echocardiography. 2016;33(3):406–415. doi: 10.1111/echo.13087
  43. Moreno J, García-Sáez JA, Clavero M, et al. Effect of breast cancer cardiotoxic drugs on left atrial myocardium mechanics. Searching for an early cardiotoxicity marker. Int J Cardiol. 2016;210:32–34. doi: 10.1016/j.ijcard.2016.02.093
  44. Setti E, Dolci G, Bergamini C, et al. P2460 prospective evaluation of atrial function by 2D speckle tracking analysis in HER-2 positive breast cancer patients during Trastuzumab therapy. Eur Heart J. 2019;40(Suppl 1):2460. doi: 10.1093/eurheartj/ehz748.0792
  45. Moustafa S, Ho TH, Shah P, et al. Predictors of Incipient dysfunction of all cardiac chambers after treatment of metastatic renal cell carcinoma by tyrosine kinase inhibitors. J Clin Ultrasound. 2016;44(4):221. doi: 10.1002/JCU.22333
  46. Anqi Y, Yu Z, Mingjun X, et al. Use of echocardiography to monitor myocardial damage during anthracycline chemotherapy. Echocardiography. 2019;36(3):495–502. doi: 10.1111/echo.14252
  47. Timóteo AT, Moura Branco L, Filipe F, et al. Cardiotoxicity in breast cancer treatment: What about left ventricular diastolic function and left atrial function? Echocardiography. 2019;36(10):1806–1813. doi: 10.1111/echo.14487
  48. Park H, Kim KH, Kim HY, et al. Left atrial longitudinal strain as a predictor of cancer therapeutics-related cardiac dysfunction in patients with breast cancer. Cardiovasc Ultrasound. 2020;18(1):1–8. doi: 10.1186/S12947-020-00210-5
  49. Di Lisi D, Cadeddu Dessalvi C, Manno G, et al. Left atrial strain and left atrial stiffness for early detection of cardiotoxicity in cancer patients. Eur Heart J. 2021;42(Suppl 1):2021. doi: 10.1093/eurheartj/ehab724.021
  50. Li VW, Lai CT, Liu AP, et al. Left atrial mechanics and integrated calibrated backscatter in anthracycline-treated long-term survivors of childhood cancers. Ultrasound Med Biol. 2017;43(9):1897–1905. doi: 10.1016/j.ultrasmedbio.2017.05.017
  51. Loar RW, Colquitt JL, Rainusso NC, et al. Assessing the left atrium of childhood cancer survivors. Int J Cardiovasc Imaging. 2021;37(1):155–162. doi: 10.1007/s10554-020-01970-x
  52. Patel NR, Chyu CK, Satou GM, et al. Left atrial function in children and young adult cancer survivors treated with anthracyclines. Echocardiography. 2018;35(10):1649–1656. doi: 10.1111/echo.14100
  53. Tadic M, Genger M, Cuspidi C, et al. Phasic left atrial function in cancer patients before initiation of anti-cancer therapy. J Clin Med. 2019;8(4):421. doi: 10.3390/JCM8040421
  54. Liao JN, Chao TF, Kuo JY, et al. Age, sex, and blood pressure-related influences on reference values of left atrial deformation and mechanics from a large-scale asian population. Circ Cardiovasc Imaging. 2017;10(10):e006077. doi: 10.1161/CIRCIMAGING.116.006077
  55. Cameli M, Mandoli GE, Loiacono F, et al. Left atrial strain: a new parameter for assessment of left ventricular filling pressure. Heart Fail Rev. 2016;21(1):65–76. doi: 10.1007/S10741-015-9520-9
  56. Singh A, El Hangouche N, McGee K, et al. Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib. Echocardiography. 2021;38(1):81–88. doi: 10.1111/echo.14946

Supplementary files

There are no supplementary files to display.


Copyright (c) 2022 Yusupova A.V., Yusupov E.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Свидетельство о регистрации СМИ ПИ № ФС 77 - 79539 от 09 ноября 2020 года выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies